Izalontamab Brengitecan Approved in China: World’s First EGFR×HER3 Bispecific ADC, a Breakthrough in Nasopharyngeal Cancer
On June 22, 2026, NMPA officially approved Biokin Pharmaceutical’s independently developed Class 1 innovative drug,…
Articles
China API Industry Overview: Key Strength Areas, Supply Chain Capabilities, and Global Market Position
Over the past two decades, the China API industry has evolved into a foundational pillar…
How to Find Generic Drug Versions in China: A Practical Guide to Verification and Availability
In the global healthcare system, generic drugs have become an important way to reduce treatment…
What Are Degrader-Antibody Conjugates (DACs)? Next-Generation ADC Technology and the Global Pipeline Landscape
The excitement surrounding antibody-drug conjugates (ADCs) has not yet faded, but a new frontier is…
The World’s Second CFB Inhibitor Lanoracopan Approved by NMPA: China-Developed PNH Therapy Marks a Breakthrough
On June 11, China’s National Medical Products Administration (NMPA) officially approved Wuhan Createrna Science and…
Gumokimab Approved for Plaque Psoriasis in China: The IL-17A Therapy Landscape Continues to Evolve
On June 11, Akeso announced that its self-developed IL-17A monoclonal antibody, Gumokimab (AK111, brand name…
New Hemophilia Drug Approved in China: Bemiltenase Alfa Becomes World’s First Factor X Activator
On June 4, 2026, the NMPA officially announced that injectable Bemiltenase alfa (STSP-0601), a Class…
Access Pathways for Innovative Medicines in China: Hospitals, Pharmacies, and Pharmaceutical Distribution Channels
More and more overseas patients are beginning to explore China’s innovative drug resources in search…
May 2026 China Innovative Drug Approvals: 5 Major New Drugs Approved
China’s innovative drug industry continues to achieve major breakthroughs. According to public information released by…
Which Cancers Does China Have Advantages In? Top 5 Areas of Strength Explained
From precision medicine to immunotherapy, from novel targeted drugs to cell therapy, China has formed…